icosapent ethyl / Generic mfg. 
Welcome,         Profile    Billing    Logout  
 26 Diseases   7 Trials   7 Trials   4331 News 
11 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
icosapent ethyl / Generic mfg.
MITIGATE, NCT04505098: A Pragmatic Randomized Trial of Icosapent Ethyl for High-Cardiovascular Risk Adults

Terminated
4
39600
US
Icosapent ethyl, Vascepa
Kaiser Permanente, Amarin Corporation
Covid19, Atherosclerosis, Cardiovascular Diseases, Upper Respiratory Tract Infections
12/22
12/22
IPE-PREVENTION, NCT04562467: The Use of Icosapent Ethyl on Vascular Progenitor Cells in Individuals With Elevated Cardiovascular Risk

Completed
4
70
Canada
Icosapent Ethyl 1000 MG Oral Capsule [Vascepa], Vascepa, IPE
Canadian Medical and Surgical Knowledge Translation Research Group, HLS Therapeutics, Inc, Unity Health Toronto, Western University, Canada
Cardiovascular Diseases, Cardiovascular Risk Factor, Triglycerides High, Diabetes Mellitus, Type 2
05/23
05/23
ARTCAP, NCT06280976: Aggressive Risk-Prevention Therapies for Coronary Atherosclerotic Plaque (ART-CAP)

Recruiting
4
200
US
Statin, atorvastatin, Aspirin tablet, aspirin 81 mg, Nexlizet, bempedoic acid-ezetimibe, LEQVIO, inclisiran, Vascepa, icosapent ethyl, Jardiance, empagliflozin, Colchicine
University of Louisville
Coronary Artery Disease, Atherosclerosis, Heart Attack
01/29
01/29
2005-002088-98: Full title of the trial : A multicentre, multi-national, double-blind, randomised, parallel group placebo-controlled trial of ethyl-EPA (ethyl-icosapent) in patients with Huntington’s Disease

 
3
100
Europe
Ethyl-EPA, LAX-101,
Amarin Neuroscience Ltd, AMARIN NEUROSCIENCE LTD
HUNTINGTON’S DISEASE
 
 
NCT04239950: Efficacy of Ethyl Icosapentate in Patients With Severe Hypertriglyceridemia

Active, not recruiting
3
300
RoW
Placebo, Ethyl Icosapentate
Mochida Pharmaceutical Company, Ltd., Sumitomo Pharma (Suzhou) Co., Ltd.
Hypertriglyceridemia
12/23
12/23
EMT2, NCT03428477 / 2016-000628-24: EPA for Metastasis Trial 2

Active, not recruiting
3
418
Europe
Icosapent Ethyl, Vascepa, Placebo
Mark A Hull, PhD FRCP, Yorkshire Cancer Research, Amarin Pharma Inc.
Liver Metastasis, Colon Cancer
11/25
04/26
BRAVE-EPA, NCT02719327: Brain Amyloid and Vascular Effects of Eicosapentaenoic Acid

Completed
2/3
131
US
icosapent ethyl (IPE), Vascepa, gel cap placebo, Placebo
VA Office of Research and Development, University of Wisconsin, Madison
Alzheimer's Disease
09/23
09/23
NCT04172636: PRevention Using EPA Against coloREctal Cancer

Not yet recruiting
2
80
NA
AMR101 (VASCEPA, icosapent ethyl), Omega-3 fatty acid
Harvard Medical School, Harvard School of Public Health
Colorectal Adenoma
10/21
10/22
SALVAGE, NCT06466278: IcoSApent ethyL to Slow Down Aortic VAlve Stenosis proGrEssion

Recruiting
2
110
Europe
Icosapent ethyl, Placebo
Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)
Aortic Valve Stenosis
07/26
12/26
NCT05198843: Testing an Omega-3 Fatty Acid-Based Anti-Cancer Therapy for Patients With Triple-Negative Inflammatory Breast Cancer That Has Spread to Other Parts of the Body

Terminated
1/2
1
US
Dasatinib, BMS-354825, Dasatinib Hydrate, Dasatinib Monohydrate, Sprycel, Icosapent Ethyl, (all-Z)-5,8,11,14,17-Eicosapentaenoic Acid Ethyl Ester, AMR 101, AMR101, Cis-Eicosapentaenoic Acid Ethyl Ester, Ethyl Icosapentate, Vascepa
National Cancer Institute (NCI)
Anatomic Stage IV Breast Cancer AJCC v8, Metastatic Triple-Negative Breast Inflammatory Carcinoma
12/23
12/23
NCT04682665: Prebiotic Effect of Eicosapentaenoic Acid Treatment for Colorectal Cancer Liver Metastases

Recruiting
N/A
250
Europe
Icosapent Ethyl Oral Capsule, Placebo
University of Leeds, National Cancer Institute (NCI), Massachusetts General Hospital, Massachusetts Institute of Technology, Harvard School of Public Health (HSPH), University of Bradford
Colon Cancer Liver Metastasis
07/24
07/25

Download Options